Zymeworks ZYME Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value at other companies

CHE

ChemedCHE

85.8-25.1%

HTF

Heartflow, Inc. Common StockHTFL

15.9+124%

KEE

Keel Infrastructure Corp. Common StockKEEL

$0.72-35.7%

BeldenBDC

$39.44+80.5%

KEE

Keel Infrastructure Corp. Common StockKEEL

$1.08+4.9%

Boston BeerSAM

$343.91-10.0%

Other financials

Income statement

See full

Revenue$2.4M-91.1%

Operating income-$47.1M-84.0%

Net income-$44.2M-95.1%

EPS (diluted)-$0.59-96.7%

Balance sheet

See full

Cash & equivalents$244.3M+221%

Total debt$17.0M-7.7%

Total equity$163.6M-49.7%

Total assets$478.2M+12.4%

Cash flow

See full

Operating cash flow-$45.7M-1,242%

CapEx$216.0K+1,250%

Free cash flow-$45.9M-1,242%

Valuation

See full

Market cap$1.79B+125%

Profitability

See full

Operating margin-140.4%+7.3pp

Net margin-126.3%+5.0pp

FCF margin-94.8%+15.5pp

Returns & leverage

See full

Return on equity-42%+29.2pp

Debt / equity0.1×0.0×

Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.

The official record: Zymeworks’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zymeworks's share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value?: Zymeworks (ZYME) reported share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value of 0 in Q4 2025.
What does share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value mean?: The weighted-average fair value of stock options granted to employees and directors, measured at the date of grant. This metric is used to assess the cost of equity-based compensation and the perceived value of the company's stock incentives.